The hepatocellular carcinoma (HCC) market in China is poised to experience a sudden explosion in market growth. Availability of existing systemic agents is limited, with only three therapy options beyond surgery or chemotherapy. However, the pipeline of emerging therapies is deep, with a large number of treatments being developed both within China and multinationally. Decision Resources Group anticipates a rapid market expansion over the next ten years, driven by immune checkpoint inhibitors such as Opdivo and Keytruda. Additionally, following the establishment of national patient coverage and streamlined procedures for drug approval, along with implementation of patent protections, it is likely that multinational companies will be increasingly incentivized to enter the growing HCC market with branded therapies compared to previous years.
- How large are the drug-treatable HCC populations and how will the drug-treatment rates change over time?
- What is the current state of the China HCC market? Which are the most important drugs and why? What are interviewed experts’ insights on current treatment options? What clinical needs remain unfulfilled? What are the current opportunities in the HCC market?
- What are the key market access considerations of the most promising pipeline products? What sales/uptake could they secure in HCC?
- What are key drivers and constraints in the China HCC market, and how will the market evolve over the forecast period?
- How do national and provincial policies affect access to oncology therapies in China?
China In-Depth: Comprehensive market intelligence providing world-class epidemiology, keen insight into the China specific access & reimbursement environment, current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Qualitative and quantitative insights driven by 5 country-specific interviews with thought-leading medical oncologists Supported by survey data collected for this and other DRG research epidemiology Diagnosed incidence of HCC by disease stage. Clinically and market relevant drug-treatable populations.
10-year, annualized, drug-level sales and patient shares of key HCC regimens through 2028, based on primary and secondary market research to formulate bottom-up assumptions
Phase III: 14 drugs. Phase II: 1 drugs. Coverage of select early-phase products.
- Hepatocellular Carcinoma | China In-Depth | China
- China In-Depth: Hepatocellular Carcinoma
Author(s): Meghan Hennis, PhD; Steven F. Trueman, PhD; Oliver Blandy
Meghan Hennis, PhD is a Senior Analyst in the New Product Development group at Decision Resources Group. She has over 10 years of research experience in the biological sciences followed by 2 years as part of the Consulting team at DRG where she provided key insights to client business questions across a range of therapeutic areas. Dr. Hennis received her in Neuroscience from University of Texas Southwestern Medical Center and her in Biology from University of North Carolina Chapel Hill.
Steve is a member of Decision Resources Group’s Infectious, Niche, and Rare Diseases (INRD) team. Currently, he provides analyses and content production on infections caused by the human immunodeficiency virus (HIV) and the hepatitis C virus (HCV). Steve conducted his postdoctoral research on models of neurodegenerative disease in the Department of Biochemistry at Brandeis University. He earned a doctorate in biochemistry from the University of Massachusetts Medical School, Graduate School of Biomedical Sciences, where he studied protein translocation into the endoplasmic reticulum.
Oliver Blandy, BSc PGCE MSc, joined Decision Resources Group (DRG) as an Associate Epidemiologist in 2017. He focuses on the epidemiology of cancer. Oliver holds an MSc from the University of Bristol where he specialized in Nutrition, Physical Activity and Public Health. He also holds a BSc in Chemistry and has a Post Graduate Certificate in Education (PGCE), both from the University of Bristol and taught general science and Advanced Chemistry in high school for two years. Before joining the team at DRG, Oliver worked as a Research Assistant for Imperial College London where he was the lead for several studies within an NIRH funded research group that investigated healthcare associated infections and antimicrobial resistance.